UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

SAT0247 Safety of RAPID Rituximab Infusion in Rheumatoid Arthritis in A Single Community Practice

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.682-682

2014

Volltextzugriff (PDF)

AB0436 Consolidated long-term safety of infliximab in inflammatory arthritis from a prospective, observational registry

Annals of the rheumatic diseases, 2018-06, Vol.77 (Suppl 2), p.1380

2018

Volltextzugriff (PDF)

AB0382 Factors Associated with the Incidence of Infusion Reactions to Infliximab: Results from “Remitrac Infusion”, A Prospective Real-World Community Registry

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.932-932

2014

Volltextzugriff (PDF)

FRI0172 Primary and Secondary Non-Response in RA Patients Treated with An anti-TNF: An Analysis from A Prospective, Observational Registry

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.491-492

2016

Volltextzugriff (PDF)

SAT0168 What is the Treatment Durability and Safety Profile of Rheumatoid Arthritis Patients Treated with Infliximab Plus Methotrexate and/or Leflunomide? An Analysis from a Real-World Registry

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.714-714

2015

Volltextzugriff (PDF)

AB0421 Outcomes of infliximab treatment in canadian rheumatoid arthritis patients of different age groups

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.661-661

2013

Volltextzugriff (PDF)

SAT0557 Predictors of Response in Patients with Psoriatic Arthritis Treated with Anti-TNF in a Real-World Setting

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.861-862

2015

Volltextzugriff (PDF)

AB1163 Prevalence of Smoking and Impact on Disease Parameters Among Ankylosing Spondylitis, Rheumatoid Arthritis and Psoriatic Arthritis Patients Treated with Infliximab or Golimumab

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.1291-1292

2015

Volltextzugriff (PDF)

FRI0204 What is the Correlation of Individual HAQ and Basdai Questions with Disease Activity Measures in Ankylosing Spondylitis? Implications for Instrument Reduction

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.498-498

2015

Volltextzugriff (PDF)

AB0302 Profile of Joint Involvement over Time in Rheumatoid Arthritis and Psoriatic Arthritis Patients Treated with Anti-TNF in A Real-World Setting

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.904-905

2014

Volltextzugriff (PDF)

SAT0035 Impact of Corticosteroid Use on Remission Sustainability and Infection Rates among Rheumatoid Arthritis Patients in Remission While on Infliximab: Treatment Implications Based on A Real-World Population

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.601-601

2014

Volltextzugriff (PDF)

AB1044 Are There Gender Specific Differences in Patient Reported Outcomes at Initiation of Golimumab Treatment in Rheumatoid Arthritis?

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.1145-1145

2014

Volltextzugriff (PDF)

FRI0047 Prediction of Remission by Patients and Physicians: Does the Doctor Know Best?

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.398-398

2014

Volltextzugriff (PDF)

THU0241 Predictors of Acr/Eular Boolean and SDAI Remission in Patients with Established Rheumatoid Arthritis Treated with Anti-TNF: an Analysis from the Prospective, Observational Registry, Biotrac

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.265-265

2014

Volltextzugriff (PDF)

AB0228 Variability in Patient Characteristics and Outcomes in Rheumatoid Arthritis upon Infliximab Treatment Based on the Size of the Biologic Treatment Registry Site

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.879-879

2014

Volltextzugriff (PDF)

AB1059 Assessing Treatment Durability of Infliximab in the Management of Psoriatic Arthritis and Rheumatoid Arthritis Patients in A Canadian Setting

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.1150-1151

2014

Volltextzugriff (PDF)

THU0179 Corticosteroid Use in Rheumatoid Arthritis Patients on Infliximab: Treatment Implications Based on a Real-World Canadian Population

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A224-A224

2013

Volltextzugriff (PDF)

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

The New England journal of medicine, 2009-08, Vol.361 (8), p.756-765

2009

Volltextzugriff (PDF)

Incidence of infusion reactions to intravenous golimumab: results from a prospective, real-world community registry

Clinical and Experimental Rheumatology, 2020-03, Vol.38 (2), p.371-371

2020

Volltextzugriff (PDF)

Physician- and Patient-reported Effectiveness Are Similar for Tofacitinib and TNFi in Rheumatoid Arthritis: Data From a Rheumatoid Arthritis Registry

Journal of rheumatology, 2022-05, Vol.49 (5), p.447-453

2022

Volltextzugriff (PDF)

Arthritis in hemochromatosis

Journal of rheumatology, 1993-03, Vol.20 (3), p.448

1993

Volltextzugriff (PDF)

Septic arthritis due to Mycobacterium marinum

Journal of rheumatology, 1994-05, Vol.21 (5), p.957

1994

Volltextzugriff (PDF)

Escherichia coli emphysematous endophthalmitis and pyelonephritis: Case report and review of the literature

The American journal of medicine, 1988-03, Vol.84 (3), p.636-639

1988

Volltextzugriff (PDF)

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

The Lancet (British edition), 2009-07, Vol.374 (9685), p.210-221

2009

Volltextzugriff (PDF)

1 – 24 von 24

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(24)
Mit Volltextzugriff
(19)

Publikationsform

Artikel
(24)

Sprache

Englisch
(24)

Erscheinungsjahr

n.n

Zeitschrift / Serie

3 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

SAT0247 Safety of RAPID Rituximab Infusion in Rheumatoid Arthritis in A Single Community Practice

AB0436 Consolidated long-term safety of infliximab in inflammatory arthritis from a prospective, observational registry

AB0382 Factors Associated with the Incidence of Infusion Reactions to Infliximab: Results from “Remitrac Infusion”, A Prospective Real-World Community Registry

FRI0172 Primary and Secondary Non-Response in RA Patients Treated with An anti-TNF: An Analysis from A Prospective, Observational Registry

SAT0168 What is the Treatment Durability and Safety Profile of Rheumatoid Arthritis Patients Treated with Infliximab Plus Methotrexate and/or Leflunomide? An Analysis from a Real-World Registry

AB0421 Outcomes of infliximab treatment in canadian rheumatoid arthritis patients of different age groups

SAT0557 Predictors of Response in Patients with Psoriatic Arthritis Treated with Anti-TNF in a Real-World Setting

AB1163 Prevalence of Smoking and Impact on Disease Parameters Among Ankylosing Spondylitis, Rheumatoid Arthritis and Psoriatic Arthritis Patients Treated with Infliximab or Golimumab

FRI0204 What is the Correlation of Individual HAQ and Basdai Questions with Disease Activity Measures in Ankylosing Spondylitis? Implications for Instrument Reduction

AB0302 Profile of Joint Involvement over Time in Rheumatoid Arthritis and Psoriatic Arthritis Patients Treated with Anti-TNF in A Real-World Setting

SAT0035 Impact of Corticosteroid Use on Remission Sustainability and Infection Rates among Rheumatoid Arthritis Patients in Remission While on Infliximab: Treatment Implications Based on A Real-World Population

AB1044 Are There Gender Specific Differences in Patient Reported Outcomes at Initiation of Golimumab Treatment in Rheumatoid Arthritis?

FRI0047 Prediction of Remission by Patients and Physicians: Does the Doctor Know Best?

THU0241 Predictors of Acr/Eular Boolean and SDAI Remission in Patients with Established Rheumatoid Arthritis Treated with Anti-TNF: an Analysis from the Prospective, Observational Registry, Biotrac

AB0228 Variability in Patient Characteristics and Outcomes in Rheumatoid Arthritis upon Infliximab Treatment Based on the Size of the Biologic Treatment Registry Site

AB1059 Assessing Treatment Durability of Infliximab in the Management of Psoriatic Arthritis and Rheumatoid Arthritis Patients in A Canadian Setting

THU0179 Corticosteroid Use in Rheumatoid Arthritis Patients on Infliximab: Treatment Implications Based on a Real-World Canadian Population

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

Incidence of infusion reactions to intravenous golimumab: results from a prospective, real-world community registry

Physician- and Patient-reported Effectiveness Are Similar for Tofacitinib and TNFi in Rheumatoid Arthritis: Data From a Rheumatoid Arthritis Registry

Arthritis in hemochromatosis

Septic arthritis due to Mycobacterium marinum

Escherichia coli emphysematous endophthalmitis and pyelonephritis: Case report and review of the literature

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

Suchergebnisse filtern